SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jeffrey Peppercorn, S Yousuf Zafar, Kevin Houck, Peter Ubel, Neal J Meropol, Does comparative effectiveness research promote rationing of cancer care?, The Lancet Oncology, 2014, 15, 3, e132

    CrossRef

  2. 2
    C M Booth, I F Tannock, Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence, British Journal of Cancer, 2014, 110, 3, 551

    CrossRef

  3. 3
    Joseph Lopez, Erin Prifogle, Theodore T. Nyame, Jacqueline Milton, James W. May, The Impact of Conflicts of Interest in Plastic Surgery, Plastic and Reconstructive Surgery, 2014, 133, 6, 1328

    CrossRef

  4. 4
    G. Glaeske, Versorgungsforschung in der Urologie, Der Urologe, 2014, 53, 12, 1735

    CrossRef

  5. 5
    Anna-Bettina Haidich, Dimitrios Pilalas, Despina G. Contopoulos-Ioannidis, John P.A. Ioannidis, Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents, Journal of Clinical Epidemiology, 2013, 66, 4, 371

    CrossRef

  6. 6
    Stephan Sahm, Of mugs, meals and more: the intricate relations between physicians and the medical industry, Medicine, Health Care and Philosophy, 2013, 16, 2, 265

    CrossRef

  7. 7
    Marlies van Lent, John Overbeke, Henk J Out, Recommendations for a uniform assessment of publication bias related to funding source, BMC Medical Research Methodology, 2013, 13, 1, 120

    CrossRef

  8. 8
    G. Glaeske, Versorgungsforschung in der Onkologie, Forum, 2013, 28, 4, 247

    CrossRef

  9. 9
    Aaron S. Kesselheim, Joy L. Lee, Jerry Avorn, Amber Servi, William H. Shrank, Niteesh K. Choudhry, Conflict of interest in oncology publications, Cancer, 2012, 118, 1
  10. 10
    F. Catalá-López, A. García-Altés, E. Álvarez-Martín, R. Gènova-Maleras, C. Morant-Ginestar, E. Arana, Evaluación económica de intervenciones en enfermedades oncológicas en España: revisión sistemática y análisis comparativo, Farmacia Hospitalaria, 2012, 36, 3, 141

    CrossRef

  11. 11
    Zhijun Xiao, Ye Zhang, Yan Wang, Feng Xu, Quality Assessment for Systematic Review /Meta-Analysis on Antidepressant Therapy Published in Chinese Journals, International Journal of Pharmacology, 2012, 8, 7, 614

    CrossRef

  12. 12
    G. Glaeske, Spektrum der Versorgungsforschung in der Onkologie, Der Onkologe, 2012, 18, 2, 105

    CrossRef

  13. 13
    Tatiana Goberstein Lerner, Michele da Costa Miranda, Andrea Thaumaturgo Lera, Aline Ueda, Bruna Briones, Auro Del Giglio, Rachel Riechelmann, The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials, Contemporary Clinical Trials, 2012, 33, 5, 1019

    CrossRef

  14. 14
    A. Batalla, I. García-Doval, B. Aranegui, A. García-Cruz, ¿Quién financia la investigación de los dermatólogos españoles? Análisis del año 2008 y comparación con otros grupos, Actas Dermo-Sifiliográficas, 2011, 102, 7, 517

    CrossRef

  15. 15
    Louis H. Barr, Jane Crofton, Yu-Hsin Annie Lin, A Community Hospital Clinical Trials Program: Infrastructure for Growth, Surgical Oncology Clinics of North America, 2011, 20, 3, 447

    CrossRef

  16. 16
    Erika P Hamilton, Jeffrey M Peppercorn, Ethical issues in adult oncology randomized clinical trials, Clinical Investigation, 2011, 1, 5, 629

    CrossRef

  17. 17
    Evangelos C. Rizos, Georgia Salanti, Dimitrios P. Kontoyiannis, John P.A. Ioannidis, Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents, Journal of Clinical Epidemiology, 2011, 64, 8, 830

    CrossRef

  18. 18
    Stephan Sahm, Of mugs, meals and more: the intricate relations between physicians and the medical industry, Medicine, Health Care and Philosophy, 2011,

    CrossRef

  19. 19
    A. Batalla, I. García-Doval, B. Aranegui, A. García-Cruz, Who Funds Research by Spanish Dermatologists? Comparative Analysis of Articles Published in 2008, Actas Dermo-Sifiliográficas (English Edition), 2011, 102, 7, 517

    CrossRef

  20. 20
    General Practice, 2011,

    CrossRef

  21. 21
    Kenneth R. Gundle, Molly J. Dingel, Barbara A. Koenig, ‘To prove this is the industry's best hope’: big tobacco's support of research on the genetics of nicotine addiction, Addiction, 2010, 105, 6
  22. 22
    Susan Hawthorne, Embedding values: how science and society jointly valence a concept—the case of ADHD, Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, 2010, 41, 1, 21

    CrossRef

  23. You have free access to this content23
    D. N. Lathyris, N. A. Patsopoulos, G. Salanti, J. P. A. Ioannidis, Industry sponsorship and selection of comparators in randomized clinical trials, European Journal of Clinical Investigation, 2010, 40, 2
  24. 24
    A. Martin, Intérêts et conflits d’intérêts: le point de vue d’un expert, Oncologie, 2010, 12, 11-12, 657

    CrossRef

  25. 25
    Athina Tatsioni, George C. M. Siontis, John P. A. Ioannidis, Partisan Perspectives in the Medical Literature: A Study of High Frequency Editorialists Favoring Hormone Replacement Therapy, Journal of General Internal Medicine, 2010, 25, 9, 914

    CrossRef

  26. 26
    Kanu Okike, Mininder S. Kocher, Erin X. Wei, Charles T. Mehlman, Mohit Bhandari, Accuracy of Conflict-of-Interest Disclosures Reported by Physicians, New England Journal of Medicine, 2009, 361, 15, 1466

    CrossRef

  27. 27
    Reshma Jagsi, Nathan Sheets, Aleksandra Jankovic, Amy R. Motomura, Sudha Amarnath, Peter A. Ubel, Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research, Cancer, 2009, 115, 12
  28. 28
    D. Edwards, A. Ballantyne, Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors, Internal Medicine Journal, 2009, 39, 3
  29. 29
    Kelly W. Mitchell, Lisa A. Carey, Jeffrey Peppercorn, Reporting of race and ethnicity in breast cancer research: room for improvement, Breast Cancer Research and Treatment, 2009, 118, 3, 511

    CrossRef

  30. 30
    Alessandro Liberati, Douglas G. Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C. Gøtzsche, John P.A. Ioannidis, Mike Clarke, P.J. Devereaux, Jos Kleijnen, David Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Journal of Clinical Epidemiology, 2009, 62, 10, e1

    CrossRef

  31. 31
    J.A. Wilson, Does Pharma Fund the Pipers? – Scottish Intercollegiate Guidelines Network (SIGN) Guidelines 90 — Diagnosis and Management of Head and Neck Cancer, October 2006, Clinical Oncology, 2008, 20, 9, 661

    CrossRef

  32. 32
    Kanu Okike, Mininder S. Kocher, Charles T. Mehlman, Mohit Bhandari, Industry-sponsored research, Injury, 2008, 39, 6, 666

    CrossRef

  33. 33
    John P.A. Ioannidis, Perfect Study, Poor Evidence: Interpretation of Biases Preceding Study Design, Seminars in Hematology, 2008, 45, 3, 160

    CrossRef

  34. 34
    Mary McLennan, Fah Che Leong, Andrew Steele, Jenine Harris, The influence of industry sponsorship on the acceptance of abstracts and their publication, American Journal of Obstetrics and Gynecology, 2008, 198, 5, 579.e1

    CrossRef

  35. 35
    Jonathan R Markman, Maurie Markman, Running an ethical trial 60 years after the Nuremberg Code, The Lancet Oncology, 2007, 8, 12, 1139

    CrossRef

  36. 36
    Jeffrey Peppercorn, Thomas G. Roberts, Tim G. Hammond, History of Clinical Trial Development and the Pharmaceutical Industry, Pharmaceutical Sciences Encyclopedia,
  37. 37
    Andreas Lundh, Sergio Sismondo, Joel Lexchin, Octavian A Busuioc, Lisa Bero, Industry sponsorship and research outcome, The Cochrane Library,